[CAS NO. 37693-01-9] Clofoctol
PRODUCTS SPECIFICATIONS [37693-01-9]
DESCRIPTION [37693-01-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 365.34 |
| Molecular Formula | C21H26Cl2O |
| SMILES | OC1=CC=C(C(C)(C)CC(C)(C)C)C=C1CC2=CC=C(Cl)C=C2Cl |
Summary
Clofoctol is a bacteriostatic antibiotic . Clofoctol is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. Clofoctol is only functional against Gram-positive bacteria and can penetrate into human lung tissue. Clofoctol is also an inhibitor of prostate cancer . Clofoctol has antiviral potency [1] [2] [3] .
In Vitro
Clofoctol (0-100 μM; 72 h) inhibits prostate cancer cell growth
[2]
.
Clofoctol (0-20 μM; 24 h) arrests cell cycle at G
1
phase
[2]
.
Clofoctol (0-30 μM; 0-24 h) induces ER stress and activates UPR pathways
[2]
.
Clofoctol (0-40 μM; 24 h) inhibits translation
[2]
.
Clofoctol (0-100 μM; 24 h) shows antiviral effect against SARS-CoV-2 with IC
50
s of 9.3 μM and 11.59 μM in Vero-81 and Vero-81-TMPRSS2 cells, respectively
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | Prostate cancer cell lines: LNCaP, DU145, PC3, LAPC4, CWR22Rv1 and C42B |
| Concentration: | 0-100 μM |
| Incubation Time: | 72 h |
| Result: | Inhibited cell growth with IC 50 values ranging from 10 to 15 μM. |
Cell Viability Assay [2]
| Cell Line: | PC3 |
| Concentration: | 0, 10 and 20 μM |
| Incubation Time: | 24 h |
| Result: | Induced a G 1 arrest. |
RT-PCR [2]
| Cell Line: | PC3 |
| Concentration: | 0, 5, 10, 15, 20 and 30 μM |
| Incubation Time: | 24 h |
| Result: | Increased the splicing of XBP-1 mRNA in PC3 cells in a dose-dependent manner. Dose-dependently decreased PstI digestion products from XBP-1 mRNA. |
Western Blot Analysis [2]
| Cell Line: | PC3 |
| Concentration: | 0, 5, 10, 15, 20, 25 and 30 μM |
| Incubation Time: | 0, 0.5, 1, 3, 6 and 9 h or 24 h (cell cycle) |
| Result: |
Dose- and time-dependently increased the level of phosphorylated eIF2α, up-regulated CHOP expression, and increased the expression of BiP.
Led to a dose-dependent decrease in the levels of cyclin A and cyclin D1. |
In Vivo
Clofoctol (175 mg/kg; i.p.; daily for 37 days) is capable of blocking tumour growth without apparent toxicity in a mouse model of human prostate cancer xenograft
[2]
.
Clofoctol (62.5 mg/kg; i.p.; twice) inhibits SARS-CoV-2 replication and lowers inflammation in lungs in mice with SARS-CoV-2 infection
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male athymic nude mice (BALB/c, nu/nu-NCr) aged 4–6 weeks, human prostate cancer xenograft model [2] |
| Dosage: | 175 mg/kg |
| Administration: | Intraperitoneal injection, daily for 37 days |
| Result: | Significantly inhibited PC3 tumour growth, tumour weight was also reduced by 60%. |
| Animal Model: | K18-hACE2 transgenic C57BL/6J mice with SARS-CoV-2 infection [3] |
| Dosage: | 62.5 mg/kg |
| Administration: | Intraperitoneal injection, 1h and 8h post-infection |
| Result: | Induced body weight loss, reduced the viral load in the lungs. The expression of transcripts encoding IL-6, TNFα, IL12p40, IFNβ, IFNγ and the interferon-stimulated genes (ISG) Mx1, Ifi44 and ISG15 was markedly reduced. |
| Animal Model: | 8–10 week-old female C57BL/6J mice [3] |
| Dosage: | 62.5mg/kg |
| Administration: | Intraperitoneal injection, once (Pharmacokinetics) |
| Result: | Reached concentrations up to 61 μM in the lungs and remained above this level for almost 4h as early as 30 min after injection. |
Appearance
Solid
Source
Bacillus subtilis
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 273.72 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7372 mL | 13.6859 mL | 27.3718 mL |
| 5 mM | 0.5474 mL | 2.7372 mL | 5.4744 mL |
| 10 mM | 0.2737 mL | 1.3686 mL | 2.7372 mL |
References
- [1] Ghilardi PL, et al. Treatment of ear, nose and throat infections with clofoctol. Drugs Exp Clin Res. 1985;11(11):815-8.
- [2] Wang M, et al. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. Br J Pharmacol. 2014 Oct;171(19):4478-89.
- [3] Belouzard S, et al. Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice. PLoS Pathog. 2022 May 19;18(5):e1010498.
Synonyms
